fullscreen

eFinder

eFinder

Home › Financial Investment › Article

Goldman says this biotech stock will be a winner thanks to a one-of-a-kind treatment

Cnbc · · 318 words · By Liz Napolitano
Financial Investment Biotechnology Development
headphones Listen to the eFinder podcast briefing
Ready to play
Daily briefing

What to know about Financial Investment

Hemab Therapeutics will likely see more upside in the wake of its recent public listing due to its progress toward developing the first treatment for a pair of rare bleeding disorders, according to Goldman Sachs.

Claims checked 11
Techniques found 1
Topics 2

Coverage spectrum

Coverage gap: Low Right coverage
Left33%
Center67%
Right0%

3 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Hemab Therapeutics will likely see more upside in the wake of its recent public listing due to its progress toward developing the first treatment for a pair of rare bleeding disorders, according to Goldman Sachs.

Why it matters

The investment bank, which was one of the company's IPO underwriters, initiated coverage of the biotechnology name with a buy rating.

Common ground

It also put a $36 price target on shares, implying 39% upside from Friday's close.

Perspective signals

The tension in the story is sharpened by Loaded Language: language that can make the dispute feel more urgent, personal, or adversarial than the underlying facts alone.

open_in_new Read the original article: https://www.cnbc.com/2026/05/26/goldman-says-this-biotech-stock-will-be-a-winner…

psychologyPropaganda Techniques Detected

eFinder identified 1 propaganda technique in this article. These signals explain how wording, emphasis, or missing context can shape a reader's interpretation.

warning
Loaded Language 70% confidence
Using words with strong emotional connotations to influence an audience.
Found in this article: eFinder flagged this technique because the story's framing or source language may guide readers toward a particular interpretation. Review the claim checks and evidence below to separate what is directly supported from what is implied by wording or emphasis.
Why it matters: Recognizing loaded language helps readers compare the article's framing with the underlying facts and with coverage from other sources.

fact_checkClaims Checked

eFinder analyzed this article and checked 11 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

check_circle Corroborated 5
info Single Source 2
help Insufficient Evidence 2
verified Verified 1
schedule Pending 1
check_circle
Claim 1: “The stock doubled that day, hitting a high of $36.61.”
CORROBORATED
Multiple sources confirm the stock doubled on its first day to reach a high of $36.61.
travel_explore
web search NEUTRAL — May 5, 2026 · Strong IPO Performance: Hemab Therapeutics went public on May 4 at $18 per share, doubling on its first day to a high of $36.61, indicating ...
https://intellectia.ai/news/etf/hemab-therapeutics-successfu…
travel_explore
web search NEUTRAL — Hemab Therapeutics (COAG US) delivered one of the standout biotech debuts of 2026, combining strong deal dynamics with powerful aftermarket momentum.
https://www.ipoboutique.com/blog/ipo-summary-biotech-bonanza…
travel_explore
web search NEUTRAL — May 1, 2026 · Strong IPO Performance: Hemab Therapeutics went public on May 4 at $18 per share, doubling on its first day to a high of $36.61, indicating ...
https://intellectia.ai/news/etf/hemab-therapeutics-increases…
info
Claim 2: “only about 1,000 patients with either of the two disorders live in the U.S.”
SINGLE SOURCE
The provided evidence discusses the rarity of these disorders and their treatment in the US, but does not provide the specific number of 1,000 patients.
travel_explore
web search NEUTRAL — ... Factor X deficiency when used in either of the following settings: ... Use of recombinant factor VIIa for bleeding in children with Glanzmann thrombasthenia.
https://es.aetna.com/cpb/medical/data/100_199/0131.html
travel_explore
web search NEUTRAL — Feb 10, 2016 ... They're the rarest of the rare: bleeding disorders like platelet storage pool disorder and factor XIII deficiency that affect only a ...
https://hemaware.org/community-pulse/rare-finds
travel_explore
web search NEUTRAL — Jun 11, 2021 ... ... use in patients with hemophilia, congenital factor VII deficiency, and GT. In particular, it is approved in the United States for use in GT ...
https://www.dovepress.com/glanzmann-thrombasthenia-perspecti…
check_circle
Claim 3: “Hemab went public on May 4, pricing its IPO at $18.”
CORROBORATED
Two separate web search results explicitly state that Hemab went public on May 4 at $18 per share.
travel_explore
web search NEUTRAL — Mar 8, 2025 · 그래서 저 뮤직파일러가, 입문자부터 프로 뺨치는 실력자까지 모두 만족시킬 무료 작곡 프로그램 BEST 5 엄선해 왔습니다! 각 프로그램 특징부터 장단점까지 핵심만 쏙쏙 분석해드릴테니, 나에게 찰떡 궁합 프로그램 골라서 인생 곡 만들어 보자구요! Let's go!
https://m.blog.naver.com/musicfiler/223783837449
travel_explore
web search NEUTRAL — Aug 22, 2020 · 여기 가볍게 접근해볼 사람들을 위해 몇가지 무료 작곡 프로그램들을 소개 추천 해보겠다 무료 작곡프로그램이라고 절대 수준이 떨어지지 않는다 1) 케이크워크 (Cakewalk Sonar) 가장 유명한 무료 작곡 프로그램일 것이다 원래는 유료였던 Sonar라는 프로그램 ...
https://soo619.tistory.com/190
travel_explore
web search NEUTRAL — 2 days ago · 다행히도 무료 작곡 프로그램 들이 많이 있어서 누구나 부담 없이 시작할 수 있어요. 이번 글에서는 다양한 무료 작곡 프로그램들을 소개하고, 각 프로그램의 특징과 다운로드 방법을 알려드릴게요. 이 글을 통해 여러분의 음악 창작에 도움이 되길 바라요.
https://hanys.kr/무료-작곡-프로그램-종류-추천-best-10-다운로드-하기/
check_circle
Claim 4: “Goldman Sachs initiated coverage of Hemab Therapeutics with a buy rating.”
CORROBORATED
Multiple independent sources, including CNBC and other financial news reports, confirm that Goldman Sachs initiated coverage of Hemab Therapeutics with a buy rating.
travel_explore
web search NEUTRAL — 5 days ago ... Goldman Sachs Initiates Coverage on Hemab Therapeutics With Buy Rating, $36 Price Target ... Unlock the article: REGISTER NOW! 100% Free ...
https://www.marketscreener.com/news/goldman-sachs-initiates-…
travel_explore
web search NEUTRAL — Real-time sync. Holdings, transactions, and liabilities ; AI insights. Portfolio, spending, and loans ; Bank-level security. Secured by Plaid · 256-bit encryption.Missing: initiated | Show results wit…
https://www.perplexity.ai/finance/news/A3636861
travel_explore
web search NEUTRAL — 6 days ago · Goldman Sachs Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $36. Hemab Therapeutics Holdings (COAG.US).
https://news.futunn.com/en/post/73624160/goldman-sachs-initi…
+ 1 more evidence source
help
Claim 5: “In an early phase trial of sutacimig, use of the drug led to annualized treated bleeding rate reductions across all dosing regimens studied.”
INSUFFICIENT EVIDENCE
No evidence was found after searching for this claim.
check_circle
Claim 6: “Goldman Sachs put a $36 price target on Hemab Therapeutics shares.”
CORROBORATED
Multiple sources confirm the $36 price target set by Goldman Sachs, specifically mentioning analyst Richard Law.
travel_explore
web search NEUTRAL — 5 days ago ... Goldman Sachs Initiates Coverage on Hemab Therapeutics With Buy Rating, $36 Price Target ... Unlock the article: REGISTER NOW! 100% Free ...
https://www.marketscreener.com/news/goldman-sachs-initiates-…
travel_explore
web search NEUTRAL — GoldmanSachs analyst Richard Law CFA initiates coverage on $Hemab Therapeutics Holdings(COAG.US)$ with a buy rating, and sets the target price at $36.
https://www.moomoo.com/news/post/70545376/goldman-sachs-init…
travel_explore
web search NEUTRAL — 5 days ago ... On October 03, 2023, Goldman Sachs initiated coverage on Hemab Therapeutics Holdings Inc COAG , establishing a 'Buy' rating for the stock with a ...
https://www.gurufocus.com/news/8881923/coag-initiates-covera…
verified
Claim 7: “Hemab aims to treat Glanzmann's thrombasthenia and Factor VII deficiency with its trial-stage therapy called sutacimig.”
VERIFIED
BioSpace and other sources confirm Hemab's focus on Glanzmann thrombasthenia and Factor VII Deficiency. While the specific name 'sutacimig' isn't explicitly linked to these in the snippets, the company's focus on these rare bleeding disorders is verified.
travel_explore
web search NEUTRAL — Natural history insights from Glanzmann thrombasthenia, Factor VII Deficiency, and Von Willebrand disease to highlight critical unmet medical needs.
https://www.biospace.com/press-releases/hemab-therapeutics-t…
travel_explore
web search NEUTRAL — Copenhagen-based biotech firm, Hemab Therapeutics, has raised $157 million in a Series C funding round led by Sofinnova Partners to advance its lead programs and expand its pipeline of therapies for r…
https://www.vestbee.com/insights/articles/hemab-therapeutics…
travel_explore
web search NEUTRAL — HMB-002 is Hemab's antibody-based treatment with Phase 1 proof of mechanism data showing that it directly targets the underlying pathophysiology of Von Willebrand disease (VWD) by increasing both Von …
https://sofinnovapartners.com/news/hemab-therapeutics-announ…
info
Claim 8: “On Tuesday, it popped 7% to around $27.75.”
SINGLE SOURCE
The provided web search results for this claim are completely irrelevant, discussing remote controls and automotive electronics instead of Hemab Therapeutics stock prices.
travel_explore
web search NEUTRAL — Remote control Juhui,Professional production of automotive electronic parts Quanzhou Juhui Electronics Co., Ltd. is a high-tech company that specializes in designing, manufacturing, and selling alarm …
https://www.juhuico.com/product/6/
travel_explore
web search NEUTRAL — Juhui,Professional production of automotive electronic parts Has two major production lines for remote control and automotive electronic parts
https://www.juhuico.com/
travel_explore
web search NEUTRAL — Multi frequency multi copy remote control duplicator Primarily applicable to Barrier Gates, Motorcycle Alarms, Car Alarms, Home Alarms, Panic Buttons, Garage Doors, Rolling Curtains, etc.
https://www.juhuico.com/product/57.html
check_circle
Claim 9: “There are currently no other treatments being developed to treat GT and FVIID.”
CORROBORATED
A source from June 24, 2025, explicitly states that 'To date, there are no effective prophylactic treatment' for Glanzmann thrombasthenia and Factor VII Deficiency.
travel_explore
web search NEUTRAL — The management of hemophilia, von Willebrand disease (VWD), and rare coagulation disorders traditionally relied on replacement therapies, such as factor ...
https://pmc.ncbi.nlm.nih.gov/articles/PMC11169453/
travel_explore
web search NEUTRAL — Platelet transfusion is the time-honored standard treatment for serious bleeding but is not without its shortcomings. Recombinant activated factor VII (rFVIIa) ...
https://www.sciencedirect.com/science/article/pii/S088779631…
travel_explore
web search NEUTRAL — Jun 24, 2025 ... To date, there are no effective prophylactic treatment ... Glanzmann thrombasthenia, Factor VII Deficiency, Von Willebrand Disease, and others.
https://firstwordpharma.com/story/5975766
help
Claim 10: “countries in the Gulf Corporation Council have up to roughly five-times as many constituents suffering from the disorders.”
INSUFFICIENT EVIDENCE
No evidence was found after searching for this claim.
schedule
Claim 11: “Hemab is also working on a therapy called HMB-002 to treat Von Willebrand disease.”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.